Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human β3 adrenergic receptor agonists with good oral bioavailability. Part II

Journal of Medicinal Chemistry

Volumn 51, Issue 13, 2008, Pages 4002-4020

  Imanishi, Masashi ^a   Itou, Shinji ^a   Washizuka, Kenichi ^a   Hamashima, Hitoshi ^a   Nakajima, Yutaka ^a   Araki, Takanobu ^a   Tomishima, Yasuyo ^b   Sakurai, Minoru ^a   Matsui, Shigeo ^a   Imamura, Emiko ^a   Ueshima, Koji ^a   Yamamoto, Takao ^a   Yamamoto, Nobuhiro ^a   Ishikawa, Hirofumi ^b   Nakano, Keiko ^a   Unami, Naoko ^a   Hamada, Kaori ^a   Matsumura, Yasuhiro ^a   Takamura, Fujiko ^a   Hattori, Kouji ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 (CYCLOHEXYLOXY) 4' [2 [[2 HYDROXY 2 (3 PYRIDINYL)ETHYL]AMINO]ETHYL] 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [(2 HYDROXY 1 METHYL 2 PHENYLETHYL)AMINO]ETHYL] 3 ISOPROPOXY 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL] 3 ISOPROPOXY 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]ETHOXY] 3 PROPOXY 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 (6 AMINO 3 PYRIDINYL) 2 HYDROXYETHYL]AMINO]ETHOXY] 3 ISOBUTYL 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 (6 AMINO 3 PYRIDINYL) 2 HYDROXYETHYL]AMINO]ETHYL] 3 ISOBUTYL 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 HYDROXY 2 (3 PYRIDINYL)ETHYL]AMINO]ETHYL] 3 ISOPROPOXY 4 BIPHENYLCARBOXYLIC ACID; 4' [2 [[2 HYDROXY 2 (3 PYRIDINYL)ETHYL]AMINO]PROPYL] 1,1' BIPHENYL 4 CARBOXYLIC ACID; 4' [2 [[2 HYDROXY 2 (3 PYRIDINYL)ETHYL]AMINO]PROPYL] 3 PROPOXY 4 BIPHENYLCARBOXYLIC ACID; AJ 9677; BENZOIC ACID DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BIPHENYL DERIVATIVE; BMS 19449; CARBACHOL; CP 331684; FK 175; KUL 7211; L 755507; L 796568; SOLABEGRON;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; OVERACTIVE BLADDER; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALKYLATION; AMINES; ANIMALS; BENZOIC ACID; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CROSS-LINKING REAGENTS; DOGS; HAPLORHINI; HUMANS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RATS; RECEPTORS, ADRENERGIC, BETA-3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46849098036     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8000345     Document Type: Article

References (35)

1. 3- adrenoceptors on brown adpocytes as target for anti-obesity drugs. Nature 1984, 309, 163-165.
2. 3-adrenergic receptor. Science 1989, 245, 1118-1121.
3. 3- adrenoceptor mRNA in human tissues. Eur. J. Pharmacol. 1995, 289, 223-228.
4. 3 adrenoceptor in the human detrusor muscle. Br. J. Pharmacol. 1999, 126, 819-825.
5. (b) Igawa, Y.; Yamazaki, Y.; Takeda, H.; Hayakawa, K.; Akahane, M.; Ajisawa, Y.; Yoneyama, T.; Nishizawa, O.; Andersson, K. E. Relaxant effects of isoproterenol and selective β3- adrenoceptor agonists on normal, low compliant, and hyperreflexic human bladders. J. Urol. 2001, 165, 240-244.
6. 3-adrenoceptor selective agonist, on relaxation of the human detrusor muscle in vitro. Neurourol. Urodyn. 2006, 25, 815-819.
7. (a) Tanaka, N.; Tamai, T.; Mukaiyama, H.; Hirabayashi, A.; Muranaka, H.; Akahane, S.; Miyata, H.; Akahane, M. J. Med. Chem. 2001, 44, 1436-1445.
8. 3-adrenoceptor agonistic activity of 4′-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. J. Med. Chem. 2003, 46, 105-112.
9. 3 -adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr. Pharm. Des. 2001, 7, 1433.
10. 3- adrenergic receptor agonists as potential therapeutic agents for obesity and type II diabetes. Prog. Med. Chem. 2003, 41, 167-189.
11. 3-adrenergic receptor agonists. Curr. Med. Chem. 2006, 13, 25-37.
12. (b) Hieble, J. P. Recent advances in identification and characterization of β-adrenoceptor agonists and antagonists. Curr. Top. Med. Chem. 2007, 7, 207-216.
13. 3-Adrenergic Receptor Agonists with Good Oral Bioavailability. Part I. J. Med. Chem. 2008, 51, 1925-1944.
14. 3 adrenergic receptor agonist. Bioorg. Med. Chem Lett. 1998, 8, 1107-1112.
15. 3 adrenergic receptor with improved pharmacokinetic properties. Bioorg. Med. Chem. Lett. 1998, 8, 2111-2116.
16. 3 Adrenergic Receptor Agonist, (R)-N-[4-[2-[[2- Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl) phenyl]thiazol-2-yl]benzenesulfonamide. J. Med. Chem. 2000, 43, 3832-3836.
17. Washburn, N. W.; Sher, M. P.; Poss, M. K.; Girotra, N. R.; McCann, J. P.; Gavai, V. A.; Mikkilineni, B. A.; Mathur, A.; Cheng, P.; Dejneka, C. T. Beta 3 agonists. Part 1: evolution from inception to BMS-194449. Bioorg. Med. Chem. Lett. 2001, 11, 3035-3039.
18. Dow, R. L. Chem. Abstr. 1998, 130, 81419 Eur. Pat. Appl. EP 887079, 1998.
19. 3-Adrenergic Receptor Agonist, [3-[(2R)-[[(2R)-(3-Chlorophenyl)-2-hydroxyethy-1]amino]propyl] -1H-indol-7-yloxy]acetic Acid. Chem. Pharm. Bull 2005, 53 (2), 184-198.
20. 3-adrenoceptor agonistic activity of 4′-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence. J. Med. Chem. 2003, 46, 105-112.
21. (a) Uehling, D. E.; Shearer, B. G.; Donaldson, K. H.; Chao, E. Y.; Deaton, D. N.; Adkison, K. K.; Brown, K. K.; Cariello, N. F.; Faison, W. L.; Lancaster, M. E.; Lin, J.; Hart, R.; Milliken, T. O.; Paulik, M. A.; Sherman, B. W.; Sugg, E. E.; Cowan, C. Biarylaniline phenethanolamines as potent and selective β3 adrenergic receptor agonists. J. Med. Chem. 2006, 49, 2758-2771.
22. 3 adrenergic receptor agonists containing heterobiaryl carboxylic acids. Bioorg. Med. Chem. Lett. 2007, 17, 4670-4677.
23. Duquette, J.; Zhang, M.; Zhu, L.; Reeves, R. S. A Scalable Asymmetric Synthesis of (R)-2-Amino-1-(3-pyridinyl)ethanol Dihydrochloride via an Oxazaborolidine Catalyzed Borane Reduction. Org. Process Res. Dev. 2003, 7 (3), 285-288.
24. 3- adrenergic agonist with a benzocycloheptene structure. Bioorg. Med. Chem. Lett. 1995, 5, 2821-2824.
25. 3 adrenergic receptor agonists. Bioorg. Med. Chem. Lett. 1998, 8, 3087-3092.
26. Vanderplas, C. B.; DeVries, M. K.; Fox, E. D.; Raggon, W. J.; Snyder, W. M.; Urban, J. F. Process Research and Scale-Up for a β3 Adrenergic Receptor Agonist. Org. Process Res. Dev. 2004, 8 (4), 583-586.
27. Taniguchi, K.; Kayakiri, H.; Fuji, N.; Hamashima, H.; Sakurai, M.; Washizuka, K.; Tomishima, Y.; Hamada, K.; Yamamoto, N.; Ishikawa, H.; Tanimura, N. WO 2001036375, 2001.
28. See Supporting Information.
29. (a) A dosing solution containing 9b, 9c, and 8b was prepared in PEG400 and the dose of each compound was 0.1 mg/kg. After administration of the dosing solution to dogs, the blood was collected and centrifuged to separate plasma. The plasma samples were analyzed by LC/MS/MS for determination of plasma concentrations of 9b, 9c, and 8b. (b) Takamura, F.; Tanaka, A.; Takasugi, H.; Taniguchi, K.; Nishio, M.; Seki, J.; Hattori, K. Metabolism investigation leading to novel drug design 2: Orally active prostacyclin mimetics. Part 5. Bioorg. Med. Chem. Lett. 2006, 16, 4475-4478.
30. Oriowo, M. A.; Chapman, H.; Kirkham, D. M.; Sennitt, M. V.; Ruffolo, R. R.; Cawthorne, M. A. The selectivity in vitro of the stereoisomers of the beta-3 adrenoceptor agonist BRL 37344. J. Pharmacol. Exp. Ther. 1996, 277, 22-27.
31. 3-adrenergic receptor agonist. Bioorg. Med. Chem. Lett. 2005, 15, 251-254.
32. 3-adrenergic receptor agonists. Bioorg. Med. Chem. Lett. 2004, 14, 3253-3240.
33. 3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity. Bioorg. Med. Chem. Lett. 2007, 17, 5245-5250.
34. Measurements of the concentration of selected compounds in plasma were measured using HPLC or LC/MS.
35. 6a our compounds are not targeted to the some CNS area because we have confirmed that our compounds have poor brain penetration.